Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Several other analysts have also recently commented on DRNA. HC Wainwright lowered their target price on Dicerna Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, April 10th. Jefferies Group LLC restated a “buy” rating and issued a $7.00 target price (down from $8.00) on shares of Dicerna Pharmaceuticals in a research report on Sunday, April 2nd. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $5.88.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 0.29% on Tuesday, reaching $3.42. The company had a trading volume of 229,081 shares. The stock has a 50 day moving average price of $3.13 and a 200-day moving average price of $2.99. The company’s market capitalization is $71.12 million. Dicerna Pharmaceuticals has a 12 month low of $2.42 and a 12 month high of $6.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.03. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.08 million. Analysts forecast that Dicerna Pharmaceuticals will post ($2.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/18/zacks-investment-research-downgrades-dicerna-pharmaceuticals-inc-drna-to-sell.html.

Several institutional investors have recently modified their holdings of DRNA. Paloma Partners Management Co boosted its position in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 53,131 shares during the period. Sabby Management LLC boosted its position in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 100,000 shares during the period. UBS Group AG boosted its position in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the period. Renaissance Technologies LLC boosted its position in shares of Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 84,682 shares during the period. Finally, Palo Alto Investors LLC boosted its position in shares of Dicerna Pharmaceuticals by 204.2% in the first quarter. Palo Alto Investors LLC now owns 481,519 shares of the biopharmaceutical company’s stock valued at $1,637,000 after buying an additional 323,240 shares during the period. Institutional investors own 55.82% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.